Xueyi LI | Partners HealthCare, Massachusetts | Department of Neurology | Research profile
Thomai Gkantiraga på LinkedIn: I didn't expect that someone could be filled with so many memories and… | 18 kommentarer
Thanos Mavros on LinkedIn: How to bolster resilience through operational technology cybersecurity
Sphingomyelin-enriched Microdomains at the Golgi Complex | Molecular Biology of the Cell
Program # Abstract Title First Name Last Name Disclosure Information AACR Distinguished Lectureship in Breast Cancer Research &q
A Putative Heterotrimeric G Protein Inhibits the Fusion of COPI-coated Vesicles - Journal of Biological Chemistry
Eva Fischer email address & phone number | GBG Forschungs GMBH Executive Vice President - Human Resources and Administration contact information - RocketReach
Quantitation of lipid content of various CHO compart- ments | Download Table
Diapositive 1
Cav-1 null mice are hyperphagic and have a normal capacity to absorb... | Download Scientific Diagram
PDF) Sphingomyelin-enriched Microdomains at the Golgi Complex | Dora Kaloyanova - Academia.edu
A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolim
A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolim
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE) - ScienceDirect
Ioannis Gkantiragas email address & phone number | GBG Forschungs GmbH Senior Clinical Project Manager, PMP contact information - RocketReach
Daniele Cordier-Stockmann email address & phone number | GBG Forschungs GMBH Accounting Assistant contact information - RocketReach
καρούλι απόσταση φιλικός ioannis gkantiragas Ξαφνική κάθοδος επίδομα Επανεμφανίστε
CAMBRIA-1-Studie zu Camizestrant bei HR+ / HER2-negativem Brustkrebs
καρούλι απόσταση φιλικός ioannis gkantiragas Ξαφνική κάθοδος επίδομα Επανεμφανίστε
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)☆ - ESMO Open
DESTINY Breast05 (GBG103) - GBG
Annual Scientific Report
Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy wit
TPA and IGF-1 enhanced the interactions of PKC with Cav-1 and Cx43 in... | Download Scientific Diagram